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Abstract
Background: The occurrence and development of hepatocellular carcinoma (HCC) depends largely on such non-
tumor factors as inflammatory condition, immune state, viral infection and liver fibrosis. Various inflammation-based
prognostic scores have been associated with survival in patients with HCC, such as the neutrophil/lymphocyte ratio
(NLR), the platelet/lymphocyte ratio (PLR) and the prognostic nutritional index (PNI). The aspartate
aminotransferase/platelet count ratio index (APRI) is thought to be a biomarker of liver fibrosis and cirrhosis. This
study aims to evaluate the ability of these indices to predict survival in HCC patients after curative hepatectomy,
and probe the increased prognostic accuracy of APRI combined with established inflammation-based prognostic
scores.
Methods: Data were collected retrospectively from 321 patients who underwent curative resection for HCC.
Preoperative NLR, PLR, PNI, APRI and clinico-pathological variables were analyzed. Univariate and multivariate
analyses were performed to identify the predictive value of the above factors for disease-free survival (DFS) and
overall survival (OS).
Results: Univariate analysis showed that NLR, PLR, PNI and APRI were significantly associated with DFS and OS in
HCC patients with curative resection. Multivariate analysis showed that NLR and APRI were superior to PLR and PNI,
and both were independently correlated with DFS and OS. Preoperative NLR >2 or APRI >1.68 predicted poor
prognosis of patients with HCC after hepatectomy. Furthermore, the predictive range of NLR combined with APRI
was more sensitive than that of either measure alone.
Conclusions: Preoperative NLR and APRI are independent predictors of DFS and OS in patients with HCC after
surgical resection. Higher levels of NLR or APRI predict poorer outcomes in HCC patients. Intriguingly, combining
NLR and APRI increases the prognostic accuracy of testing.
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Background
Hepatocellular cancer (HCC) is one of the most com-
mon and most aggressive malignancies, the third leading
cause of cancer-related deaths worldwide [1, 2]. Unlike
other solid malignancies, most HCCs result from
chronic liver disease [3], and the outcome of HCC de-
pends in part on impaired liver function secondary to
the above pathogenic condition, rather than solely to the
tumor burden. Though Tumor Node Metastasis (TNM)
staging system is an effective independent prognostic
factor for HCC, its prognostic value is limited and lag-
ging. A reliable prognostic index is therefore needed in
routine clinical practice.
In addition to the intrinsic properties of cancer cells,
host-related factors are increasingly recognized to influ-
ence the progression of tumors [4, 5]. For example, a
systemic inflammatory response can impact tumor de-
velopment through the inhibition of apoptosis, promo-
tion of angiogenesis, and damage to the DNA. The
pathogenesis of HCC is based on inflammation often
caused by hepatotropic virus infection or ethanol con-
sumption. Moreover, 70-90 % of HCCs are a result of
cirrhosis [6, 7]. In recent studies, inflammation-based
prognostic scores, such as the combination of albumin
and lymphocyte counts used in the prognostic nutri-
tional index (PNI) [5, 8], the combination of neutrophil
and lymphocyte counts in the neutrophil/ lymphocyte
ratio (NLR) [9–11], and the combination of platelet
(PLT) and lymphocyte counts in the PLT/lymphocyte ra-
tio (PLR) [12], have proved valuable in HCC prediction.
In addition, recent studies [13–15] suggest that a simple
and accurate biochemical marker of liver fibrosis and
cirrhosis, i.e., the aspartate aminotransferase (AST)/ PLT
count ratio index (APRI), may be 1) an indicator of post-
operative prognosis in early stage hepatitis B (HBV)-re-
lated HCC patients, or 2) a marker of HCC risk in HBV
patients,.
However, few studies have compared the prognostic
value of these indices to predict tumor recurrence and
survival after curative resection for HCC. Indeed, the
combination of APRI and inflammation-based prognos-
tic scores may increase the accuracy of prognosis predic-




A total of 321 histologically proven HCC patients with
hepatic resection from our hospital were recruited be-
tween 2006 and 2009. Written informed consent was ob-
tained from all patients and this study complied with the
standards of the Helsinki Declaration and current ethical
guidelines and was approved by the Institutional Ethical
Board of First Affiliated Hospital of Sun Yat-sen
University. Routine assessment was performed within
seven days before surgery, including a complete physical
examination, hematologic and biochemistry profiles,
chest X-ray, abdominal ultrasound and computed tom-
ography (CT) or magnetic resonance imaging (MRI).
Eligibility criteria included: the International Union
Against Cancer (seventh edition) TNM stage I, II, IIIA
or IIIB [16]; Child-Pugh class A hepatic function; age
18-80 years; and written informed consent. Exclusion
criteria included: TNM stage IIIC, IVA or IVB; existing
second malignancy or history of second malignancy
within the past five years; hematologic disorders; peri-
operative dysfunction of vital organs; or percutaneous
ablation, transcatheter arterial chemoembolization
(TACE), chemotherapy or radiotherapy within one
month after surgery.
Blood samples were obtained before initial treatment
to determine albumin, AST, alanine aminotransferase
(ALT), total bilirubin (TBIL), white blood cell count,
neutrophil count, lymphocyte count, platelet (PLT)
count, prothrombin time and the a-fetoprotein (AFP)
level. NLR, PLR, PNI and APRI were calculated using
the following formulas:
NLR ¼ Neutrophil count=lymphocyte count;
PLR ¼ PLT count=lymphocyte count;
PNI ¼ 10 serum albumin g=dlð Þ þ 0:005
 total lymphocyte count per mm3ð Þ; and
APRI ¼ AST IU=Lð Þ=upper limit normal½ =PLT 109=Lð Þ  100:
Treatment and follow-up
Hepatectomy was defined as radical when there was no
evidence of distant metastases and tumor clearance was
complete both macroscopically and histologically. All
patients were regularly followed up according to institu-
tional practice, including liver ultrasound, chest X-ray
and serum AFP every three months, and contrast CT
every 6 months. Tumor relapse was defined by clinical,
radiological and/or pathological diagnosis. After diag-
nosing recurrence, salvage treatments were selected, in-
cluding re-operation, percutaneous ablation or TACE.
Statistical analysis
Statistical analysis was performed using SPSS for Win-
dows version 20.0 (SPSS, Chicago, IL, USA). Receiver
operating characteristic (ROC) curve analysis was per-
formed to select the most appropriate cut-off values for
NLR, PLR, PNI and APRI to stratify patients at a high
risk of death. The χ2 test was used to compare categor-
ical variables. Disease-free survival (DFS) was calculated
from the date of surgery to the date of recurrence, and
overall survival (OS) from the date of surgery to the date
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of HCC-associated death. The Kaplan-Meier method
was used to estimate the survival rates for different
groups, and the equivalences of the survival curves were
tested by log-rank statistics. The Cox proportional haz-
ards model was used for univariate and multivariate sur-
vival analyses. P < 0.05 was considered statistically
significant.
Results
Patient and tumor characteristics
The study included 285 male patients (88.8 %) and 36 fe-
male patients (11.2 %). The mean age was 51 years (range
21-79 years). A total of 235 patients (73.2 %) developed re-
currence and 202 patients (62.9 %) died during follow up.
Hepatitis B surface antigen (HBsAg) was positive in 281
patients (87.5 %) and cirrhosis in 253 (78.8 %) patients. In-
creased AFP levels (≥200 μg/L) were observed in 182 pa-
tients (56.7 %), and 95 patients (29.6 %) had multiple
tumor masses. Mean tumor size was 87.6 mm (range 10-
300 mm) in greatest diameter, and 210 (65.4 %) patients
had tumors ≥ 50 mm in diameter. According to the
Edmonson–Steiner stage of tumor differentiation, 248
(77.3 %) patients were in stages I–II and 73 (22.7 %) pa-
tients were in stages III–IV. Likewise, according to TNM
classification, 185 patients were in TNM stage I and 137
patients in TNM stage II-III (Table 1).
Determination of cut-off value
Using 5-year overall survival rate as an endpoint, stratifi-
cation of each prognostic index was calculated by ROC
curve analyses, according to the maximum joint sensitiv-
ity and specificity values based on the peak and cut-off
points. Our results indicated that the optimal cut-off
values for NLR, PLR, PNI and APRI were 2, 115, 45 and
1.68, respectively (Fig. 1).
Independent prognostic factors for HCC
To further identify the risk factors linked to postoperative
DFS and OS, NLR, PLR, PNI, APRI and 17 clinico-
pathologic factors were evaluated by univariate analysis and
the Cox regression model. Univariate analysis showed that
the significant prognostic factors for DFS in HCC patients
were HBsAg, AFP, TNM stage, tumor number, portal vein
tumor thrombus (PVTT), tumor differentiation, intraopera-
tive blood loss, NLR, PLR, PNI and APRI (all P < 0.05).
Similarly, the significant factors for OS for those with HCC
were gender, AFP, ALT, TNM stage, tumor number, PVTT,
tumor differentiation, resection margin, intraoperative
blood loss, NLR, PLR, PNI and APRI (all P < 0.05). After
multivariate analysis, we found that AFP, TNM, PVTT,
NLR and APRI were significant independent predictors of
DFS (all P < 0.05), while TNM, PVTT, NLR, PLR and APRI
were significant independent predictors of OS (all P < 0.05)
(Tables 1 and 2).
Correlation between preoperative NLR or APRI and 17
clinico-pathologic characteristics in HCC
In order to further understand the prognostic value of
preoperative NLR or APRI on HCC patients after resec-
tion, the relationships between NLR or APRI and 17
clinico-pathologic characteristics were analyzed. A
NLR > 2 was more frequently observed in patients with
high serum AFP levels (P = 0.015), with tumor size >
5 cm (P < 0 .001), those with PVTT (P = 0 .026), with
recurrence (P = 0.005), with PNI ≤ 45 (P < 0.001) and
with PLR > 115 (P < 0.001). Likewise, an APRI > 1.68
was associated with HBsAg (P = 0.015), a low PLT
level (P < 0.001), a high ALT level (P < 0.001), TBIL
(P = 0.003), cirrhosis (P = 0.001), PVTT (P < 0.001),
recurrence (P = 0.001) and PNI ≤ 45 (P < 0.001)
(Table 3).
Overall and disease free survival rates according to NLR
or APRI
To determine the ability of NLR and APRI to predict OS
and DFS, the 321 HCC patients were divided into two
groups according to their NLR profiles: the NLR ≤ 2 group
(n = 153) and the NLR > 2 group (n = 168). Using the
Kaplan-Meier method to analyze patient survival, we found
that the 1-, 3- and 5-year DFS rates of the NLR ≤ 2 group
were markedly higher than those of the NLR > 2 group
(53.6 %, 39.2 % and 34.6 % vs 36.9 %, 23.2 % and 20.6 %, re-
spectively, P < 0.001) (Fig. 2a), while the 1-, 3- and 5-year
OS rates of the NLR ≤ 2 group were also significantly higher
than those of the NLR > 2 group (79.7 %, 58.8 % and 49.6 %
vs 63.1 %, 35.1 % and 29.7 %, respectively, P < 0.001)
(Fig. 2b). Our findings therefore indicated that high NLR
levels were correlated with a low survival rate in patients
with HCC.
Likewise, the HCC patients were divided into two
groups according to their APRI profiles: the APRI ≤ 1.68
group (n = 108) and the APRI > 1.68 group (n = 213). The
1-, 3- and 5-year DFS rates of the APRI ≤ 1.68 group were
markedly higher than those of the APRI > 1.68 group
(57.4 %, 40.7 % and 37.8 % vs 38.5 %, 25.8 % and 21.9 %,
respectively, P < 0.001) (Fig. 3a). Also, the 1-, 3- and 5-
year OS rates of the APRI ≤ 1.68 group were significantly
higher than those of the APRI > 1.68 group (83.3 %,
59.3 % and 51.8 % vs 64.8 %, 39.9 % and 32.8 %, respect-
ively, P < 0.001) (Fig. 3b). A high APRI level therefore im-
plied poor DFS and OS in HCC patients with
hepatectomy.
The prognostic value of NLR combined with APRI for HCC
after hepatectomy
To analyze the prognostic value for HCC survival of
combining NLR and APRI, we set up NLR ≤ 2 or APRI ≤
1.68 as the score of 0 and NLR > 2 or APRI > 1.68 as the
score of 1. After combining NLR with APRI, patients
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Table 1 Prognostic factors for DFS and OS by univariate analysis
Variables n DFS P OS P
1-yr 3-yrs 5-yrs 1-yr 3-yrs 5-yrs
Gender
Male 285 43.5 % 29.8 % 25.8 % 0.096 69.5 % 44.6 % 37.1 % 0.026
Female 36 55.6 % 38.9 % 38.9 % 83.3 % 61.1 % 55.6 %
Age(yrs)
< 60 244 43.9 % 32.4 % 29.5 % 0.565 70.1 % 47.1 % 39.7 % 0.677
≥ 60 77 48.1 % 26.0 % 20.3 % 74.0 % 44.2 % 37.6 %
HBsAg
Positive 281 42.0 % 29.5 % 25.4 % 0.049 69.4 % 44.8 % 38.0 % 0.123
Negative 40 65.0 % 40.0 % 40.0 % 82.5 % 57.5 % 47.5 %
AFP(μg/L)
< 200 139 54.0 % 36.7 % 34.5 % 0.002 77.7 % 51.8 % 45.3 % 0.015
≥ 200 182 37.9 % 26.4 % 21.8 % 65.9 % 42.3 % 34.5 %
ALT(U/L)
< 80 265 47.5 % 32.4 % 28.5 % 0.108 73.2 % 49.8 % 41.8 % 0.019
≥ 80 56 32.1 % 23.2 % 21.4 % 60.7 % 30.4 % 26.8 %
Hb(g/L)
≤ 120 57 33.3 % 19.3 % 17.5 % 0.068 70.2 % 35.1 % 29.8 % 0.215
> 120 264 47.3 % 33.3 % 29.4 % 71.2 % 48.9 % 41.2 %
WBC(×109)
< 10 287 46.0 % 31.7 % 27.8 % 0.384 72.1 % 46.3 % 39.6 % 0.795
≥ 10 34 35.3 % 23.5 % 23.5 % 61.8 % 47.1 % 35.3 %
Lymphocyte(×109)
< 4 313 44.7 % 30.7 % 27.0 % 0.475 71.2 % 46.3 % 39.2 % 0.988
≥ 4 8 50.0 % 37.5 % 37.5 % 62.5 % 50.0 % 37.5 %
TNM
I 184 60.9 % 42.9 % 39.1 % <0.001 84.8 % 61.4 % 55.4 % <0.001
II-III 137 23.4 % 14.6 % 11.3 % 52.6 % 26.3 % 17.4 %
Cirrhosis
No 68 41.2 % 27.9 % 25.0 % 0.541 76.5 % 47.1 % 38.2 % 0.745
Yes 253 45.8 % 31.6 % 27.9 % 69.6 % 46.2 % 39.5 %
PVTT
No 263 52.5 % 35.7 % 31.8 % <0.001 79.5 % 52.9 % 45.6 % <0.001
Yes 58 10.3 % 8.6 % 6.9 % 32.8 % 17.2 % 10.1 %
Tumor number
single 226 54.0 % 38.5 % 34.0 % <0.001 77.0 % 54.9 % 48.6 % <0.001
multiple 95 23.2 % 12.5 % 11.0 % 56.8 % 26.3 % 16.7 %
Tumor size(cm)
< 5 111 69.4 % 51.4 % 43.9 % <0.001 88.4 % 68.7 % 60.7 % <0.001
≥ 5 210 31.9 % 20.0 % 18.5 % 61.4 % 34.3 % 27.5 %
Complication
No 273 44.7 % 32.6 % 28.4 % 0.356 72.2 % 46.9 % 40.6 % 0.345
Yes 48 45.8 % 20.8 % 20.8 % 64.6 % 43.8 % 31.0 %
Tumor differentiation
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were allocated into three groups. Patients with both
NLR ≤ 2 and APRI ≤ 1.68 were calculated to have a score
of 0, and were recruited into group 1. Patients with
NLR > 2 and APRI ≤ 1.68 or with NLR ≤ 2 and APRI >
1.68 were in Group 2, with the total score of 1. Finally,
those with both NLR > 2 and APRI > 1.68 were in Group
3 with the total score of 2 (Table 4). Patients in Group 1
had the best DFS and OS rates, followed by those in
Group 2; patients in Group 3 had the worst prognosis.
The 1-, 3- and 5-year DFS rates of Group 1 (65.5 %,
52.7 % and 50.9 %, respectively) were significantly higher
than those of Group 2 (47.4 %, 30.3 % and 24.7 %,
Table 1 Prognostic factors for DFS and OS by univariate analysis (Continued)
I-II 248 49.2 % 34.3 % 30.5 % 0.001 73.4 % 49.6 % 43.5 % 0.003
III-IV 73 30.1 % 19.2 % 16.4 % 63.0 % 35.6 % 24.5 %
Resection margin(cm)
< 2 184 42.1 % 26.8 % 23.4 % 0.138 69.9 % 41.5 % 34.3 % 0.041
≥ 2 137 48.2 % 35.7 % 32.0 % 72.3 % 52.6 % 45.2 %
Intraoperative blood loss(ml)
≤ 1000 247 77.3 % 51.8 % 44.9 % <0.001 50.2 % 35.2 % 31.4 % <0.001
> 1000 74 50.0 % 28.4 % 20.1 % 27.0 % 16.2 % 13.5 %
NLR
≤ 2 153 53.6 % 39.2 % 34.6 % <0.001 79.7 % 58.8 % 49.6 % <0.001
> 2 168 36.9 % 23.2 % 20.6 % 63.1 % 35.1 % 29.7 %
PLR
≤ 115 182 51.1 % 36.3 % 31.2 % 0.01 75.8 % 54.9 % 46.7 % 0.002
> 115 139 36.7 % 23.7 % 22.2 % 64.7 % 35.3 % 29.4 %
APRI
≤ 1.68 108 57.4 % 40.7 % 37.8 % <0.001 83.3 % 59.3 % 51.8 % <0.001
> 1.68 213 38.5 % 25.8 % 21.9 % 64.8 % 39.9 % 32.8 %
PNI
≤ 45 68 33.8 % 16.0 % 11.9 % 0.002 66.2 % 36.8 % 26.3 % 0.006
> 45 253 47.8 % 34.8 % 31.2 % 72.3 % 49.0 % 42.6 %
TNM Tumor Node Metastasis, AFP Alpha-fetoprotein, HBsAg hepatitis B surface antigen, PLT platelet, PVTT portal vein tumor thrombi, NLR neutrophil/lymphocyte
ratio, PLR platelet/lymphocyte ratio, PNI prognostic nutritional index, APRI Aspartate aminotransferase /platelet count ratio index
Fig. 1 Determination of the cut-off value for NLR, PLR, PNI, APRI in
HCC patients with hepatic resection
Table 2 Independent prognostic factors for DFS and OS by the
multivariate Cox proportional hazards regression model
Variables DFS OS
HR 95%CI P HR 95%CI P
PLR 1.407 1.039-1.907 0.027
AFP 1.317 1.006-1.724 0.045
TNM 1.981 1.469-2.672 <0.001 2.326 1.680-3.220 <0.001
PVTT 1.771 1.229-2.553 0.002 1.732 1.185-2.531 0.005
NLR 1.405 1.076-1.833 0.012 1.473 1.083-2.004 0.014
APRI 1.449 1.083-1.939 0.012 1.612 1.165-2.230 0.004
HR hazard ratio, CI confidence interval, TNM Tumor Node Metastasis, AFP
Alpha-fetoprotein, PVTT portal vein tumor thrombi, NLR neutrophil/lymphocyte
ratio, PLR platelet/lymphocyte ratio, PNI prognostic nutritional index, APRI
Aspartate aminotransferase (AST)/platelet count ratio index
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Table 3 Correlation between preoperative NLR, APRI and clinico-pathologic characteristics in HCC
Variables Cases NLR P value APRI P value
≤2 >2 ≤1.68 >1.68
Age(yrs)
≥ 60 77 32(41.6 %) 45(58.4 %) 0.219 24(31.2 %) 53(68.8 %) 0.598
< 60 244 121(49.6 %) 123(50.4 %) 84(34.4 %) 160(65.6 %)
Gender
Male 285 135(47.4 %) 150(52.6 %) 0.766 92(32.3 %) 193(67.7 %) 0.146
Female 36 18(50.0 %) 18(50.0 %) 16(44.4 %) 20(55.6 %)
HCC family history
Yes 24 8(33.3 %) 16(66.7 %) 0.144 8(33.3 %) 16(66.7 %) 0.973
No 297 145(48.8 %) 152(51.2 %) 100(33.7 %) 197(66.3 %)
HBsAg
Positive 281 134(47.7 %) 147(52.3 %) 0.982 86(30.6 %) 195(69.4 %) 0.002
Negative 40 19(47.5 %) 21(52.5 %) 22(55.0 %) 18(45.0 %)
ALT(U/L)
< 80 265 126(47.5 %) 139(52.5 %) 0.928 104(39.2 %) 161(60.8 %) <0.001
≥ 80 56 27(48.2 %) 29(51.8 %) 4(7.1 %) 52(92.9 %)
TBIL(μmol/L)
< 34.2 294 144(49.0 %) 150(51.0 %) 0.119 106(36.1 %) 188(63.9 %) 0.003
≥ 34.2 27 9(33.3 %) 18(66.7 %) 2(7.4 %) 25(92.6 %)
PLT(×109)
≥ 100 292 136(46.6 %) 156(53.4 %) 0.215 108(37.0 %) 184(63.0 %) <0.001
< 100 29 17(58.6 %) 12(41.4 %) 0(0.0 %) 29(100.0 %)
Cirrhosis
Yes 253 126(49.8 %) 127(50.2 %) 0.139 74(29.2 %) 179(70.8 %) 0.001
No 68 27(39.7 %) 41(60.3 %) 34(50.0 %) 34(50.0 %)
AFP(μg/L)
≥ 200 182 76(41.8 %) 106(58.2 %) 0.015 57(31.3 %) 125(68.7 %) 0.313
< 200 139 77(55.4 %) 62(44.6 %) 51(36.7 %) 88(63.3 %)
Tumor size(cm)
> 5 210 76(36.2 %) 134(63.8 %) <0.001 65(31.0 %) 145(69.0 %) 0.160
≤ 5 111 77(69.4 %) 34(30.6 %) 43(38.7 %) 68(61.3 %)
Tumor number
Single 226 112(49.6 %) 114(50.4 %) 0.295 80(35.4 %) 146(64.6 %) 0.305
Multiple 95 41(43.2 %) 54(56.8 %) 28(29.5 %) 67(70.5 %)
TNM
I 184 96(52.2 %) 88(47.8 %) 0.061 70(38.0 %) 114(62.0 %) 0.053
II-III 137 57(41.6 %) 80(58.4 %) 38(27.7 %) 99(72.3 %)
Differentiation
I-II 248 119(48.0 %) 129(52.0 %) 0.832 85(34.3 %) 163(65.7 %) 0.660
III-IV 73 34(46.6 %) 39(53.4 %) 23(31.5 %) 50(68.5 %)
PVTT
Yes 58 20(34.5 %) 38(65.5 %) 0.026 7(12.1 %) 51(87.9 %) <0.001
No 263 133(50.6 %) 130(49.4 %) 101(38.4 %) 162(61.6 %)
Recurrence
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respectively, P = 0.001) and Group 3 (31.6 %, 21.1 %
and 19.2 %, respectively, P < 0.001). Similarly, the 1-,
3- and 5-year OS rates of Group 1 (87.3 %, 69.1 %
and 65.5 %, respectively) were also significantly
higher than those of Group 2 (76.3 %, 51.3 % and
39.3 %, respectively, P = 0.002) and Group 3 (56.1 %,
28.9 % and 26.3 %, respectively, P < 0.001) (Fig. 4a and b).
Furthermore, we found that the 1-, 3- and 5-year DFS and
OS rates of Group 2 were both significantly higher than
those of Group 3 (P = 0.013 and P = 0.002).
Discussion
Surgical resection is the mainstay of curative therapy
for HCC. However, it is well understood that malnu-
trition is of particular concern in patients with HCC
due to the concomitant underlying fibrosis and cir-
rhosis [17]. In addition, hepatectomy can cause a
series of postoperative changes in the metabolic,
endocrine, neuroendocrine and immune systems,
which can impair immunological functions and con-
tribute to an increased risk of postoperative complica-
tions and metastasis in HCC patients after surgery.
Theoretically, malnutrition, immunological status, fi-
brosis and cirrhosis may act as predictors of survival
in HCC patients after curative resection.
Increasing evidence seems to indicate that the host in-
flammatory response is correlated with the occurrence
and development of HCC, so that it can serve to predict
the clinical outcomes of patients with HCC. Several
studies have shown that an elevated NLR is associated
with poor prognosis in patients with HCC undergoing
surgical resection [18], transplantation [19], transarterial
chemoembolisation [20] and radiofrequency ablation [9].
PNI was first reported by Onodera et al. in Japan for the
assessment of the immunologic and nutritional status of
patients [21]. Pinato et al. [5] first demonstrated that
PNI was useful for assessing prognosis in patients with
HCC. Chan et al. [8] indicated that PNI was a significant
Table 3 Correlation between preoperative NLR, APRI and clinico-pathologic characteristics in HCC (Continued)
Yes 235 101(43.0 %) 134(57.0 %) 0.005 67(28.5 %) 168(71.5 %) 0.001
No 86 52(60.5 %) 34(39.5 %) 41(47.7 %) 45(52.3 %)
PNI
≤ 45 68 15(22.1 %) 53(77.9 %) <0.001 10(14.7 %) 58(85.3 %) <0.001
> 45 253 138(54.5 %) 115(45.5 %) 98(38.7 %) 155(61.3 %)
PLR
≤ 115 182 118(64.8 %) 64(35.2 %) <0.001 55(30.2 %) 127(69.8 %) 0.137
> 115 139 35(25.2 %) 104(74.8 %) 53(38.1 %) 86(61.9 %)
Complication
No 273 130(47.6 %) 143(52.4 %) 0.970 92(33.7 %) 181(66.3 %) 0.960
Yes 48 23(47.9 %) 25 (52.1 %) 16(33.3 %) 32(66.7 %)
Fig. 2 Relationship between NLR and DFS/OS of HCC patients after hepatectomy. a DFS of patients with NLR > 2 was significantly shorter than
those with NLR≤ 2 (P < 0.001, log-rank test). b OS of patients with NLR > 2 was also markedly shorter than those with NLR≤ 2 (P < 0.001,
log-rank test)
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prognostic factor for OS and DFS of patients with very
early/early stage HCC receiving curative surgery. Oka-
mura and colleagues [22] further pointed out that NLR
and PNI were predictors of overall survival in patients
who had undergone hepatectomy for HCC with curative
intent. PLR is proposed to be a predictor of thrombotic
and inflammatory conditions, thus making it an attract-
ive inflammation-related biomarker for tumors also. For
HCC, Xue et al. [23] indicated that a high baseline PLR
is a useful predictor of poor survival in patients under-
going chemoembolization. Xia et al. [24] also found that
a high level of pre-transplant PLR was associated with
advanced tumor stage and aggressive tumor behavior,
making it a useful indicator for post-transplant HCC
recurrence.
In our study, we compared the prognostic value of
various inflammation markers, based on prognostic
scores for NLR, PLR and PNI. We found that
preoperative NLR, PLR and PNI were all significant
prognostic factors for DFS and OS in patients with
HCC. High levels of NLR (>2), high levels of PLR (>115)
and low levels of PNI (≤45) predicted poor prognosis in
HCC patients with curative resection. However, NLR
was superior in this aspect to PLR and PNI; what is
more, NLR was the only independent predictive factor
for both DFS and OS in HCC patients. In addition, PLR
was the only independent predictive factor for OS in
HCC patients. We also found a significant correlation
between NLR and several clinico-pathological character-
istics: AFP, PVTT, tumor size, tumor encapsulation, re-
currence, PNI and PLR.
A three-step process of hepatitis → liver fibrosis/
cirrhosis → HCC is believed to be the primary mech-
anism of hepatocarcinogenesis. Wu and colleagues
[25] reported that high viral loads and hepatic inflam-
matory activity were associated with late HCC recur-
rence and that tumor factors were associated with
early HCC recurrence. Hung et al. [26] found that
the degree of liver fibrosis is associated with tumor
recurrence as well as with overall survival in small
and solitary HBV-related HCC patients with surgical
resection. Although liver biopsy is the gold standard
for the assessment of liver fibrosis, it is a high-risk
procedure and usually complicated by pain, bleeding,
hemothorax, bile duct injury or risk of penetration of
the abdominal viscera. In addition, sampling errors
and inter-observer variation decrease the reliability of
liver biopsy as a predictive tool. Recently, APRI was
validated as a simple, feasible, noninvasive way to as-
sess the degree of liver fibrosis in patients with
chronic hepatitis B or C [27, 28]. APRI was also
found to be a prognostic biomarker in small HCC
Fig. 3 Relationship between APRI and DFS/OS of HCC patients after hepatectomy. a DFS of patients with APRI > 1.68 was significantly shorter than those
with APRI≤ 1.68 ( P< 0.001, log-rank test). b OS of patients with APRI > 1.68 was also markedly shorter than those with APRI≤ 1.68 ( P< 0.001,
log-rank test)
Table 4 A novel and accurate predictor for HCC: the









0 Low risk of mortality
1 Intermediate risk of mortality
2 High risk of mortality
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patients after radiofrequency ablation therapy and sur-
gical resection [14, 29]. APRI was also found useful
in predicting HCC risk in patients with nonalcoholic
fatty liver disease [30] or HBV.
Our results showed that APRI was superior to PLR or
PNI as an independent predictor of both DFS and OS in
HCC patients with hepatectomy. APRI > 1.68 predicted a
short DFS and OS in HCC patients. In correlation ana-
lysis, we found that, as in previous studies [27, 28], APRI
was intimately associated with cirrhosis and HBV status.
High APRI levels predicted the condition of cirrhosis and
HBV infection. In addition, high APRI levels were posi-
tively correlated to PVTT, incomplete tumor encapsula-
tion and tumor relapse, and negatively correlated to PNI.
As mentioned above, the non-tumor factors, including
inflammatory condition, immune state, viral infection
and liver fibrosis, play an important role in determining
tumor recurrence in HCC patients. Accordingly, NLR
and APRI were both independent predictors of both
DFS and OS in HCC patients. Given that NLR is an ac-
curate inflammatory marker, and APRI can assess the
degree of liver fibrosis, we hypothesize that the combin-
ation of NLR and APRI reflects the range of non-tumor
factors, thereby enabling more precise prediction of out-
comes in HCC patients with curative resection.
Excitingly, our results showed that the combination of
NRL and APRI has a better prognostic value than either
one alone. For example, the data showed that patients in
Group 1 (both NLR ≤ 2 and APRI ≤ 1.68) had the best
DFS and OS rates, with 1-, 3- and 5-year DFS rates of
65.5 %, 52.7 % and 50.9 %, respectively, and 1-, 3- and 5-
year OS rates of 87.3 %, 69.1 % and 65.5 %, respectively.
However, the prognosis was worst in patients in Group
3 (both NLR > 2 and APRI > 1.68), whose 1-, 3- and 5-
year DFS rates were only 31.6 %, 21.1 % and 19.2 %, re-
spectively, and whose 1-, 3- and 5-year OS rates were
only 56.1 %, 28.9 % and 26.3 %, respectively. The out-
comes for patients in Group 2 (both NLR > 2 and
APRI ≤ 1.68, or both NLR ≤ 2 and APRI > 1.68), fell be-
tween those of the above two groups, with 1-, 3- and 5-
year DFS rates of 47.4 %, 30.3 % and 24.7 %, respectively,
and 1-, 3- and 5-year OS rates of 76.3 %, 51.3 % and
39.3 %, respectively. Furthermore, the difference between
any two groups was significant. So the combination of
NLR and APRI inevitably possesses both accurate and
clinically meaningful prognostic value for HCC patients
with curative resection, for example, both NLR > 2 and
APRI > 1.68 represents high risk of mortality, both
NLR ≤ 2 and APRI ≤ 1.68 represents low risk of mortal-
ity, and the other represents intermediate risk of mortal-
ity. It is very easy and valuable to accurately predict the
prognosis of HCC patients in clinical. Its mechanisms
may be that the combination of NLR and APRI reflects
most of non-tumor factors, including inflammatory con-
dition, immune state, viral infection and liver fibrosis,
rather than a certain aspect of non-tumor factors. So we
can speculate that the combination of NLR and APRI is
useful to guide the follow-up and further treatment of
HCC patients after curative resection. For example, we
should follow up closely so as to find the early tumor re-
currence for the patients with both NLR > 2 and APRI >
1.68. It may be better to follow up once a month for this
kind of patients. Even we can give some initiative treat-
ments to these patients, such as TACE, systemic chemo-
therapy, or cellular immunotherapy, etc.
Certainly, the present study has some limitations. First,
it is a retrospective, single- institution study with a rela-
tively small number of patients. A well-designed,
Fig. 4 The combination of NLR and APRI was found to enhance prognostic accuracy for HCC. Disease-free survival curves (panel a) and overall
survival curves (panel b). Group1, both NLR≤ 2 and APRI≤ 1.68; Group2, both NLR > 2 and APRI≤ 1.68 or both NLR≤ 2 and APRI > 1.68; Group3,
both NLR > 2 and APRI > 1.68
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prospective study with a larger number of patients with
HCC who underwent radical surgery is needed. Second,
we were not able to split our data set into a training
data set and a test data set for statistical validation
because of the small number of patients. So it is
worthwhile to conduct additional studies to validate
our findings and test their clinical applicability in
HCC treatment in the future.
Conclusions
In summary, our study determined that NLR and
APRI were superior to PNI and PLR, and were inde-
pendent predictors of the prognosis for HCC patients
with curative resection. Their high levels predicted
poor outcomes in HCC patients: early recurrence and
short lifetime. Excitingly, NLR combined with APRI
was more sensitive than either scale alone in predict-
ing DFS and OS in patients with HCC. The combin-
ation of NLR and APRI may be a useful prognostic
tool to determine survival in patients with HCC after
resection, and to further guide their follow-up and
postoperative treatment.
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